<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Med</journal-id><journal-title>Journal of Translational Medicine</journal-title><issn pub-type="epub">1479-5876</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1479-5876-5-70</article-id><article-id pub-id-type="pmid">18162130</article-id><article-id pub-id-type="doi">10.1186/1479-5876-5-70</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Oldenburg</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>janolde@ulrik.uio.no</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Kraggerud</surname><given-names>Sigrid M</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>Sigrid.M.Kraggerud@rr-research.no</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Bryd&#x000f8;y</surname><given-names>Marianne</given-names></name><xref ref-type="aff" rid="I5">5</xref><xref ref-type="aff" rid="I6">6</xref><email>marianne.brydoy@helse-bergen.no</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Cvancarova</surname><given-names>Milada</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>miladacv@math.uio.no</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Lothe</surname><given-names>Ragnhild A</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>rlothe@radium.uio.no</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Fossa</surname><given-names>Sophie D</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>s.d.fossa@klinmed.uio.no</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Clinical Cancer Research, The Norwegian Radiumhospital, Oslo, Norway</aff><aff id="I2"><label>2</label>Faculty of medicine, University of Oslo, 0310 Oslo, Norway</aff><aff id="I3"><label>3</label>Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radiumhospital, and University of Oslo, Norway</aff><aff id="I4"><label>4</label>Centre for Cancer Biomedicine, University of Oslo, Norway</aff><aff id="I5"><label>5</label>Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway</aff><aff id="I6"><label>6</label>Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway</aff><aff id="I7"><label>7</label>Section of Biostatistics, The Norwegian Radiumhospital, Oslo, Norway</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>27</day><month>12</month><year>2007</year></pub-date><volume>5</volume><fpage>70</fpage><lpage>70</lpage><ext-link ext-link-type="uri" xlink:href="http://www.translational-medicine.com/content/5/1/70"/><history><date date-type="received"><day>1</day><month>11</month><year>2007</year></date><date date-type="accepted"><day>27</day><month>12</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Oldenburg et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Oldenburg et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Oldenburg Jan janolde@ulrik.uio.no </dc:author><dc:title> Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>Journal of Translational Medicine 5(1): 70-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1479-5876(2007)5:1&#x0003c;70&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1479-5876</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>To assess the impact of polymorphisms in Glutathione S-transferase (GST) -P1, -M1, and -T1 on self-reported chemotherapy-induced long-term toxicities in testicular cancer survivors (TCSs).</p></sec><sec sec-type="methods"><title>Methods</title><p>A total of 238 TCSs, who had received cisplatin-based chemotherapy at median twelve years earlier, had participated in a long-term follow-up survey which assessed the prevalence of self-reported paresthesias in fingers/toes, Raynaud-like phenomena in fingers/toes, tinnitus, and hearing impairment. From all TCSs lymphocyte-derived DNA was analyzed for the functional A&#x02192;G polymorphism at bp 304 in <italic>GSTP1</italic>, and deletions in <italic>GST-M1 </italic>and <italic>GST-T1</italic>. Evaluation of associations between GST polymorphisms and self-reported toxicities included adjustment for prior treatment.</p></sec><sec><title>Results</title><p>All six evaluated toxicities were significantly associated with the cumulative dose of cisplatin and/or bleomycin. Compared to TCSs with either <italic>GSTP1-AG </italic>or <italic>GSTP1</italic>-<italic>AA</italic>, the 37 TCSs with the genotype <italic>GSTP1-GG</italic>, were significantly less bothered by paresthesias in fingers and toes (p = 0.039, OR 0.46 [0.22&#x02013;0.96] and p = 0.023, OR 0.42 [0.20&#x02013;0.88], respectively), and tinnitus (p = 0.008, OR 0.33 [0.14&#x02013;0.74]). Furthermore, absence of functional GSTM1 protected against hearing impairment (p = 0.025, OR 1.81 [1.08&#x02013;3.03]).</p></sec><sec><title>Conclusion</title><p>In TCSs long-term self-reported chemotherapy-induced toxicities are associated with functional polymorphisms in <italic>GSTP1 </italic>and <italic>GSTM1</italic>. Hypothetically, absence of GST-M1 leaves more glutathione as substrate for the co-expressed GST-P1. Also intracellular inactivation of pro-apoptotic mediators represents a possible explanation of our findings. Genotyping of these GSTs might be a welcomed step towards a more individualized treatment of patients with metastatic testicular cancer.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The progress of cisplatin-based chemotherapy has changed the once dark prospects of disseminated testicular cancer (TC) into a model of a curable neoplasm [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. This success story of oncological treatment however, is shadowed by an increase in reports on long-term somatic and psychosocial sequalae in testicular cancer survivors (TCSs) [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Cisplatin (C) is the cornerstone of chemotherapeutic treatment of TC. It has usually been combined with bleomycin (B), and vinblastine (V) as CVB regimen, until Williams et al. 1987 demonstrated that substitution of vinblastine by etoposide (E) as BEP regime resulted in increased survival and less toxicities [<xref ref-type="bibr" rid="B5">5</xref>]. While peripheral neurotoxicity can be induced by several of these drugs [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B8">8</xref>], ototoxicity (tinnitus and/or impaired hearing) is mainly ascribed to cisplatin [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. Clinicians have observed large inter-individual variations of treatment-induced toxicities among patients after similar chemotherapy regimens. In animal models these variations have been greater than explainable by variable pharmacokinetic properties [<xref ref-type="bibr" rid="B11">11</xref>]. These observations led to the assumption of genetic differences in the elimination, detoxification and/or toleration of cytotoxic agents among patients.</p><p>Glutathione S-Transferases (GSTs) are enzymes which have been linked to both the etiology of testicular cancer [<xref ref-type="bibr" rid="B12">12</xref>], the cure rate of platinum-based chemotherapy [<xref ref-type="bibr" rid="B13">13</xref>], and chemotherapy-induced toxicities [<xref ref-type="bibr" rid="B14">14</xref>]. GSTs are expressed in the testicles and levels of GTP1 are increased in case of acquired resistance to cisplatin [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. GSTs might moderate toxicities systemically but expression of these enzymes at the affected site increases the credibility of potential associations. GST-M1 and GST-P1 are both expressed at the corti organ,[<xref ref-type="bibr" rid="B17">17</xref>] which is affected in case of cisplatin-induced ototoxicity. Both enzymes are also expressed in dorsal root ganglion cells,[<xref ref-type="bibr" rid="B18">18</xref>] which are known to be damaged by cisplatin [<xref ref-type="bibr" rid="B19">19</xref>]. Further functions of GSTs have been reviewed in detail elsewhere [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. We considered germ-line polymorphisms within GST genes as promising candidates for the exploration of the large inter-individual variability of long-term treatment toxicities. Recently, we reported on their importance for cisplatin-induced audiometric assessed hearing impairment [<xref ref-type="bibr" rid="B22">22</xref>]. In the present study we aimed to investigate the relevance of functional genotype polymorphisms of <italic>GST-M1,-P1 and-T1 </italic>for the prevalence of self-reported long-term paresthesias, Raynaud-like phenomena, tinnitus, and hearing impairment in a large sample of cisplatin-based chemotherapy treated TCSs.</p></sec><sec><title>Methods and patients</title><sec><title>Patients</title><p>During the years 1998 to 2002, all Norwegian TCSs treated between 1980 and 1994 and aged between 18 and 75 years were invited to participate in a long-term survey, which consisted of a questionnaire and an out-patient visit. Patients with evidence of active TC, extragonadal germ cell malignancy, bilateral TC, a second non-germ cell malignancy (except skin cancer), and those, in whom the non-affected testicle had been removed previously due to a benign condition, were excluded [<xref ref-type="bibr" rid="B23">23</xref>]. Post-orchiectomy treatment was principally applied according to specified protocols as described previously [<xref ref-type="bibr" rid="B24">24</xref>]. Most patients treated by chemotherapy received cisplatin (C) in combination with bleomycin (B), etoposide (E) or vinblastine (V) as 3&#x02013;4 courses of BEP or CVB. These regimens were applied in conjunction with a rigorous hydration regime in all patients. For the purpose of the present study, the type of regimen, cumulative dosage per square meter body surface [mg/m<sup>2</sup>] of the most commonly used cytotoxic substances, exact number of cycles and dates of application were retrieved from treatment charts. The present study includes only TCSs, who have been treated with cisplatin-based chemotherapy at the Norwegian Radium Hospital (NRH) and for whom lymphocytes have been available for DNA analyses.</p></sec><sec><title>Genotyping</title><p>Whole blood EDTA samples were collected from the TCSs, lymphocyte-DNA extracted, and submitted to genetic analyses of functional polymorphisms in the genes coding for <italic>GSTT1</italic>, -<italic>M1</italic>, and -<italic>P1</italic>. 173 of the 238 TCSs included in this study are the same as those previously reported by us [<xref ref-type="bibr" rid="B22">22</xref>]. The known inherited homozygous deletions in <italic>GSTT1 </italic>and <italic>GSTM1 </italic>are equivalent to non-functional enzymes. A functional single nucleotide polymorphism (SNP) in the <italic>GSTP1 </italic>gene at base pair 315 between Adenosine (A) and Guanine (G) leads to the expression of either isoleucine (Ile) or valine (Val) at codon 105 (Ile105, Val105).</p><p>GST analysis was performed according to a previously described multiplex PCR protocol [<xref ref-type="bibr" rid="B25">25</xref>]. Briefly, 50&#x02013;100 ng DNA and 30 pmol of each of the primers for <italic>GSTM1</italic>, <italic>GSTT1</italic>, and <italic>GSTP1</italic>, and 10 pmol of the GSTmu2 antisense primer, 1.4 mM MgCl<sub>2</sub>, PCR buffer II from Perkin Elmer (MgCl<sub>2 </sub>free), and 0.75 Units Taq polymerase were mixed. The fragment lengths of the PCR products were 480 base pairs (bp) for <italic>GSTT1</italic>, 294 for <italic>GSTP1</italic>, 275 for <italic>GSTM1</italic>, and 175 bp for <italic>GSTM2 </italic>which served as a positive PCR control. Subsequently, 20 &#x003bc;l of the PCR product (unpurified) was digested with 8 Units of the restriction enzyme Alw261 (MBI Fermentas, USA), and the fragments were separated by agarose (4%) gel (NuSieve 3:1, FCM Bioproducts, Rockland, ME, USA) electrophoresis. The PCR products of <italic>GSTT1 </italic>and <italic>GSTM2 </italic>remain uncut, whereas the <italic>GSTP1 </italic>fragment is cut into 234 bp and 60 bp if codon 105 contains a G (guanine). <italic>GSTM1 </italic>contains a nonpolymorphic Alw1261 restriction site and therefore the PCR product is digested to 195 and 80 bp long fragments in all samples positive for <italic>GSTM1 </italic>alleles, (<italic>GSTM1</italic><bold><italic>+</italic></bold>).</p></sec><sec><title>Questionnaire module (SCIN)</title><p>In this study we use a TC specific quality of life (QLQ) module which was designed by Fossa et al. and used together with the EORTC QLQ-C30 [<xref ref-type="bibr" rid="B26">26</xref>]. This module was based on interviews with TCSs and reviews of the available literature on long-term morbidity in TCSs and was subsequently slightly modified and psychometrically evaluated. It covers six symptoms (items), figure <xref ref-type="fig" rid="F1">1</xref>, and is named: <underline>S</underline>cale for <underline>C</underline>hemotherapy-<underline>I</underline>nduced <underline>N</underline>eurotoxicity (SCIN) [<xref ref-type="bibr" rid="B27">27</xref>]. Summation of all six item scores, ranging from 0 to 3, yields the SCIN-total-score which we consider representing the overall chemotherapy-induced neurotoxicity. In the present study we divided the SCIN-total-score into three symptom-classes: none (0&#x02013;5), moderate (6&#x02013;9), and severe (10&#x02013;18).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Prevalence paresthesias in the fingers and toes, Raynaud-like phenomena in the toes, and tinnitus in TCSs depending on the GSTP1-GG genotype, statistical testing by &#x003c7;<sup>2</sup>-trends.</p></caption><graphic xlink:href="1479-5876-5-70-1"/></fig><p>The SCIN's psychometric properties have been validated and were considered suitable for its application as screening instrument for chemotherapy-induced neurotoxicity [<xref ref-type="bibr" rid="B27">27</xref>].</p></sec><sec><title>Statistical analyses</title><p>The above described item scores and the total-SCIN-score represent ordered categorical variables. Associations between genotypes and these scales were studied using Chi-square tests and ordinal logistic regression analyses (OLR), the latter approach allowing adjustment for age, and chemotherapy parameters. The risk of an increment within these scales attributed to specific parameters was expressed as odds ratio (OR) with 95% confidence interval (CI). Continuous variables were not normally distributed and are described with median and range. Each of the response variables was analyzed once such that correction for multiple testing was not required. P-values &#x0003c; 0.05 were considered significant, P-values &#x02265; 0.05 and &#x0003c; 0.10 were reported as of marginal statistical significance. All tests were two-tailed and the analyses were performed using SPSS program version 12.0.2.</p></sec><sec><title>Ethics</title><p>The Committee for Medical Ethics of Health Region II of Norway approved the protocol of the study. All patients provided informed consent to participate in the study.</p></sec></sec><sec><title>Results</title><p>A total of 238 TCS were eligible for the present study (median age at diagnosis 29 years, range 15&#x02013;64 years, table <xref ref-type="table" rid="T1">1</xref>). The median cumulative cisplatin dose was 397 mg/m<sup>2 </sup>(range: 81&#x02013;1571 mg/m<sup>2</sup>). The majority (82%) of patients received not more than one regimen of chemotherapy, which in 87% of such cases comprised BEP (44%) or CVB (44%) and consisted usually of three to four cycles (table <xref ref-type="table" rid="T2">2</xref>). The SCIN was completed at median 12 years (range: 4&#x02013;19 years) after initial diagnosis.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Demographics of the 238 cisplatin-treated TCSs</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">Age at diagnosis, years Median (range)</td><td align="left">29.3 (14.6 &#x02013; 63.6)</td></tr><tr><td align="left">Observation time, months Median (range)</td><td align="left">11.8 (4.3 &#x02013; 19.3)</td></tr><tr><td align="left">Age at survey, years Median (range)</td><td align="left">42.3 (22.7 &#x02013; 73.4)</td></tr><tr><td align="left">Histology, number (%)</td><td align="left">Seminoma: 44 (18.5%)<break/>Non-seminoma: 194 (81.5%)</td></tr><tr><td align="left">Stage according to Royal Marsden Hospital, number of patients (%)</td><td align="left">I: 72 (30.2%, incl. 2 IM)</td></tr><tr><td></td><td align="left">II: 101 (42.4%)</td></tr><tr><td></td><td align="left">III: 13 (5.5%)</td></tr><tr><td></td><td align="left">IV: 52 (21.8%)</td></tr><tr><td align="left">Number of cycles of chemotherapy</td><td align="left">1&#x02013;3: 52 (21.8%)<break/>4: 141 (59.2%)<break/>5&#x02013;7: 34 (14.3%)<break/>&#x0003e;8: 11 (4.6%)</td></tr><tr><td align="left">First Regimen (n = 238)<break/>Completed by 100% of TCSs</td><td align="left">BEP: 104 (43.7%), CVB: 104 (43.7%), BOPVIP: 10 (4.2%), Others: 20 (8.4%)</td></tr><tr><td align="left">Second Regimen (n = 44)<break/>Completed by 18.5% of TCSs</td><td align="left">BEP: 17 (39%), VIP: 12 (27%), EP: 5 (11%), Others: 10 (23%)</td></tr><tr><td align="left">Third regimen (n = 8)</td><td align="left">VIP: 2, EP: 2, Others: 4</td></tr><tr><td align="left">Fourth Regimen (n = 1)</td><td align="left">EP: 1</td></tr><tr><td align="left">Number of TCSs exposed to the most common cytotoxic agents and cumulative doses among those [mg/m2], median (range)</td><td align="left">Cisplatin (n = 238) : 397 (81 &#x02013; 1571)<break/>Bleomycin (n = 226) : 145 (29&#x02013;212)<break/>Vinblastine (n = 105) : 35 (10&#x02013;51)<break/>Etoposide (n = 146) : 1434 (41&#x02013;4934)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Association of SCIN-total-score with GST genotypes, age, and chemotherapy parameters by Ordinal Logistic Regression analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" colspan="3"><bold>Categorical variables</bold></td><td align="left" colspan="3"><bold>Symptoms class of SCIN-total-score</bold></td><td align="left" colspan="2"><bold>Univariate</bold></td><td align="left" colspan="2"><bold>Multiple</bold>&#x02020;</td></tr></thead><tbody><tr><td align="left" colspan="2"><bold>GST genotype</bold></td><td align="left"><bold>Number (%)</bold></td><td align="left"><bold>No (0&#x02013;5)</bold></td><td align="left"><bold>Moderate (6&#x02013;9)</bold></td><td align="left"><bold>Severe (10&#x02013;18)</bold></td><td align="left"><bold>P</bold></td><td align="left"><bold>OR (95% CI)</bold></td><td align="left"><bold>P</bold></td><td align="left"><bold>OR (95% CI)</bold></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left">P1</td><td align="left"><bold>A/A</bold></td><td align="left">99 (41.6)</td><td align="left">60 (60.6)</td><td align="left">23 (23.2)</td><td align="left">16 (16.2)</td><td align="left">0.098</td><td align="left">2.03 (0.88&#x02013;4.67)</td><td align="left"><bold>0.012</bold></td><td align="left"><bold>3.84 (1.34&#x02013;10.75)</bold></td></tr><tr><td></td><td align="left"><bold>A/G</bold></td><td align="left">102 (42.9)</td><td align="left">53 (52.0)</td><td align="left">29 (28.4)</td><td align="left">20 (19.6)</td><td align="left">0.014</td><td align="left">2.83 (1.24&#x02013;6.46)</td><td align="left"><bold>0.003</bold></td><td align="left"><bold>4.95 (1.70&#x02013;14.45)</bold></td></tr><tr><td></td><td align="left"><bold>G/G</bold></td><td align="left">37 (15.5)</td><td align="left">27 (73.0)</td><td align="left">10 (27.0)</td><td align="left">0 (0)</td><td align="left" colspan="4">Reference for <italic>GSTP1-AA </italic>and <italic>-AG</italic></td></tr><tr><td align="left">T1</td><td align="left"><bold>+</bold></td><td align="left">201 (84.5)</td><td align="left">118 (58.7)</td><td align="left">51 (25.4)</td><td align="left">32 (15.9)</td><td align="left">0.770</td><td align="left">1.11 (0.55&#x02013;2.22)</td><td align="left">0.714</td><td align="left">1.17 (0.50&#x02013;2.73)</td></tr><tr><td></td><td align="left"><bold>- (ref.)</bold></td><td align="left">37 (15.5)</td><td align="left">22 (59.5)</td><td align="left">11 (29.7)</td><td align="left">4 (10.8)</td><td></td><td></td><td></td><td></td></tr><tr><td align="left">M1</td><td align="left">+</td><td align="left">134 (56.3)</td><td align="left">79 (59.0)</td><td align="left">35 (26.1)</td><td align="left">20 (14.9)</td><td align="left">0.947</td><td align="left">0.98 (0.59&#x02013;1.63)</td><td align="left">0.166</td><td align="left">1.56 (0.83&#x02013;2.94)</td></tr><tr><td></td><td align="left"><bold>- (ref.)</bold></td><td align="left">104 (43.7)</td><td align="left">61 (58.7)</td><td align="left">27 (26.0)</td><td align="left">16 (15.4)</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left" colspan="2"><bold>Continuous variables</bold></td><td align="left"><bold>TCSs N (%)</bold></td><td align="left"><bold>Median</bold></td><td align="left"><bold>Minimum</bold></td><td align="left"><bold>Maximum</bold></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left" colspan="2">Age at survey (OR for 10 years)</td><td align="left">238 (100%)</td><td align="left">42.3</td><td align="left">22.7</td><td align="left">73.4</td><td align="left">0.008</td><td align="left">1.40 (1.09&#x02013;1.80)</td><td align="left"><bold>0.002</bold></td><td align="left"><bold>1.70 (1.22&#x02013;2.36)</bold></td></tr><tr><td align="left">OR*</td><td align="left">Cisplatin</td><td align="left">238 (100%)</td><td align="left">397</td><td align="left">81</td><td align="left">1571</td><td align="left">&#x0003c;0.001</td><td align="left">1.35 (1.11&#x02013;1.49)</td><td align="left"><bold>0.014</bold></td><td align="left"><bold>1.35 (1.06&#x02013;1.71)</bold></td></tr><tr><td></td><td align="left">Bleomycin</td><td align="left">226 (95.0%)</td><td align="left">142</td><td align="left">0</td><td align="left">212</td><td align="left">0.040</td><td align="left">1.65 (1.00&#x02013;2.72)</td><td align="left"><italic>0.078</italic></td><td align="left"><italic>1.43 (0.93&#x02013;2.13)</italic></td></tr><tr><td></td><td align="left">Vinblastine</td><td align="left">133 (55.9%)</td><td align="left">9.9</td><td align="left">0</td><td align="left">51</td><td align="left">0.535</td><td align="left">1.49 (0.41&#x02013;6.05)</td><td align="left">0.319</td><td align="left">0.23 (0.01&#x02013;4.14)</td></tr><tr><td></td><td align="left">Etoposide</td><td align="left">92 (38.7%)</td><td align="left">727</td><td align="left">0</td><td align="left">4934</td><td align="left">0.092</td><td align="left">1.00 (1.00&#x02013;1.00)</td><td align="left">0.918</td><td align="left">1.00 (0.90&#x02013;1.11)</td></tr></tbody></table><table-wrap-foot><p>*cumulative dose steps: bleomycin (100.000 IE/m<sup>2</sup>), cisplatin (100 mg/m<sup>2</sup>).</p><p>&#x02020; Significant associations (<bold>bold</bold>), marginal significance (<italic>italics</italic>)</p></table-wrap-foot></table-wrap><p>In univariate ORL analysis, cumulative doses of cisplatin and bleomycin as well as age at survey were significantly associated with the three-categorical SCIN-total-score (table <xref ref-type="table" rid="T2">2</xref>). In multivariate analysis only age at survey and cumulative dose of cisplatin remained significant. Furthermore, polymorphisms in <italic>GSTP1 </italic>had considerable impact: TCSs with <italic>GSTP1-AA </italic>or <italic>GSTP1-AG </italic>had a more than three-fold risk of a more severe symptom-class than those with <italic>GSTP1-GG</italic>. Neither presence of functional GSTT1 nor of functional GSTM1 was significantly associated with the SCIN-total-score.</p><p>The cumulative dose of cisplatin was significantly associated with paresthesias in the toes, Raynaud-like phenomena in the toes and with both tinnitus and hearing impairment (table <xref ref-type="table" rid="T3">3</xref>). The risk of a more severe symptom-class increased by roughly 1.3 for each step of 100 mg/m<sup>2 </sup>cumulative cisplatin, the dose corresponding to one cycle of chemotherapy. Age at survey was significantly associated with the severity of each item except from tinnitus. Paresthesias in fingers/toes as well as tinnitus and hearing impairment were significantly associated with polymorphic alleles of <italic>GSTP1 </italic>and/or <italic>GSTM1</italic>. Presence of functional <italic>GSTT1 </italic>was not associated with any of the item-scores. Functional <italic>GSTM1 </italic>increased the risk of hearing impairment by 1.8 (table <xref ref-type="table" rid="T3">3</xref>). Furthermore, paresthesias in both fingers and toes as well as Raynaud-like phenomena in the toes showed a trend towards such an association.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Association of SCIN items and relevant variables by ordinal Logistic Regression analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left" colspan="2">Age (OR for decadal steps)</td><td align="left" colspan="2">Cisplatin (OR for steps of 100 mg/m<sup>2</sup>)</td><td align="left" colspan="2"><italic>GSTM1 </italic>(+ vs.- as Reference)</td><td align="left" colspan="2"><italic>GSTT1 </italic>(+ vs.- as Reference)</td><td align="left" colspan="2"><italic>GSTP1 </italic>(GG vs. AA/AG as Reference)</td></tr></thead><tbody><tr><td></td><td align="left">P</td><td align="left">OR (95%CI)*</td><td align="left">P</td><td align="left">OR (95% CI)*</td><td align="left">P</td><td align="left">OR (95% CI)*</td><td align="left">P</td><td align="left">OR</td><td align="left">P</td><td align="left">OR (95% CI)*</td></tr><tr><td colspan="11"><hr></hr></td></tr><tr><td align="left">Paresthesias fingers</td><td align="left"><bold>0.046</bold></td><td align="left"><bold>1.29 (1.01&#x02013;1.67)</bold></td><td align="left">0.178</td><td align="left">1.11 (0.95&#x02013;1.29)</td><td align="left"><italic>0.057</italic></td><td align="left"><italic>1.68 (0.98&#x02013;2.76)</italic></td><td align="left">0.926</td><td align="left">1.03</td><td align="left"><bold>0.039</bold></td><td align="left"><bold>0.46 (0.22&#x02013;0.96)</bold></td></tr><tr><td align="left">Paresthesias toes</td><td align="left"><bold>&#x0003c;0.001</bold></td><td align="left"><bold>1.82 (1.40&#x02013;2.37)</bold></td><td align="left"><bold>&#x0003c;0.001</bold></td><td align="left"><bold>1.34 (1.14&#x02013;1.57)</bold></td><td align="left"><italic>0.050</italic></td><td align="left"><italic>1.68 (1.00&#x02013;2.81)</italic></td><td align="left">0.704</td><td align="left">0.88</td><td align="left"><bold>0.023</bold></td><td align="left"><bold>0.42 (0.20&#x02013;0.88)</bold></td></tr><tr><td align="left">Raynaud's P. fingers</td><td align="left"><italic>0.058</italic></td><td align="left"><italic>1.27 (0.99&#x02013;1.62)</italic></td><td align="left"><bold>0.021</bold></td><td align="left"><bold>1.27 (1.03&#x02013;1.39)</bold></td><td align="left">0.235</td><td align="left">1.35</td><td align="left">0.944</td><td align="left">0.98</td><td align="left">0.920</td><td align="left">0.97</td></tr><tr><td align="left">Raynaud's P. toes</td><td align="left"><bold>0.022</bold></td><td align="left"><bold>1.34 (1.04&#x02013;1.72)</bold></td><td align="left"><bold>&#x0003c;0.001</bold></td><td align="left"><bold>1.33 (1.14&#x02013;1.56)</bold></td><td align="left"><italic>0.072</italic></td><td align="left"><italic>1.60 (0.96&#x02013;2.66)</italic></td><td align="left">0.355</td><td align="left">0.73</td><td align="left"><italic>0.052</italic></td><td align="left"><italic>0.49 (0.24&#x02013;1.01)</italic></td></tr><tr><td align="left">Tinnitus</td><td align="left">0.153</td><td align="left">1.20</td><td align="left"><bold>0.001</bold></td><td align="left"><bold>1.32 (1.12&#x02013;1.55)</bold></td><td align="left">0.962</td><td align="left">1.01</td><td align="left">0.107</td><td align="left">1.83</td><td align="left"><bold>0.008</bold></td><td align="left"><bold>0.33 (0.14&#x02013;0.74)</bold></td></tr><tr><td align="left">Hearing Impairment</td><td align="left"><bold>&#x0003c;0.001</bold></td><td align="left"><bold>1.61 (1.24&#x02013;2.09)</bold></td><td align="left"><bold>&#x0003c;0.001</bold></td><td align="left"><bold>1.34 (1.14&#x02013;1.56)</bold></td><td align="left">0.025</td><td align="left">1.81 (1.08&#x02013;3.03)</td><td align="left">0.595</td><td align="left">1.20</td><td align="left">0.553</td><td align="left">0.81</td></tr></tbody></table><table-wrap-foot><p>*(95% CI) only listed when the association was statistically significant (<bold>bold</bold>) or marginally significant (<italic>italics</italic>)</p></table-wrap-foot></table-wrap><p>Presence of both <italic>GSTP1-G </italic>alleles reduced the risk of peripheral paresthesias in the fingers and in the toes, and of tinnitus by at least the factor two. The association between Raynaud-like phenomena in the toes was of a similar magnitude, but only of marginal significance. No symptom was significantly different between TCSs with <italic>GSTP1-AG </italic>and <italic>GSTP1-AA </italic>(data not shown).</p><p>In order to illustrate these relations we depicted the scorings of TCSs with either one or none <italic>GSTP1-G </italic>alleles (n = 201) opposed to those with both alleles (n = 37), figure <xref ref-type="fig" rid="F2">2</xref>. Statistical analysis by &#x003c7;2 tests for trends revealed significantly protective effect of <italic>GSTP1</italic>-<italic>G </italic>homozygosity against paresthesias in the fingers and toes (p = 0.040 and p = 0.025, respectively), Raynaud-like phenomena in the toes (p = 0.032), and tinnitus (p = 0.003).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p>SCIN and its six items with the four possible scores.</p></caption><graphic xlink:href="1479-5876-5-70-2"/></fig></sec><sec><title>Discussion</title><p>After cisplatin-based chemotherapy, the risk of self-reported peripheral paresthesias, Raynaud-like phenomena in the toes, and tinnitus is halved in TCSs homozygous for <italic>GSTP1-G </italic>compared to those with GSTP1-AA/AG. Furthermore, presence of functional <italic>GSTM1 </italic>nearly doubled the risk of hearing impairment.</p><p><italic>GSTP1-GG </italic>proved highly protective against chemotherapy-induced tinnitus (OR = 0.33). Cisplatin leads to loss of outer hair cells in the cochlea [<xref ref-type="bibr" rid="B28">28</xref>], and thereby also to hearing impairment [<xref ref-type="bibr" rid="B4">4</xref>], which was limited by absence of <italic>GSTM1</italic>. In the subgroup of 173 TCSs in whom audiometry was performed such a beneficial effect of non-functional <italic>GSTM1 </italic>was found for objectively measured cisplatin-induced hearing impairment, which in addition was strongly associated with the genotype <italic>GSTP1-GG </italic>[<xref ref-type="bibr" rid="B22">22</xref>]. However, in the present study <italic>GSTP1-GG </italic>did not protect against self-reported hearing impairment. One possible explanation for this lack of association might be a higher sensitivity of audiometric determination of hearing thresholds at 4000 Hz &#x02013; opposed to self-reported hearing impairment. The cisplatin-induced hearing impairment affects preferentially high frequencies which are no prerequisite for language communication and might thus, despite a measurable deterioration, not be noticed by the affected individuals. Tinnitus appears to be a more sensitive symptom for subjectively experienced cisplatin-induced ototoxicity and its prevalence usually increases with the individual's age [<xref ref-type="bibr" rid="B29">29</xref>]. In our TCSs however, the cisplatin-dose is of overriding importance causing <italic>GSTP1-GG </italic>to disclose its protective potential.</p><p>Paresthesias may represent a sequel to several drugs applied in our TCSs: Oncovin, vinblastine, and etoposide [<xref ref-type="bibr" rid="B30">30</xref>]. Cisplatin-induced paresthesias are experienced by length-dependent symmetrical stocking distribution of sensory symptoms [<xref ref-type="bibr" rid="B30">30</xref>]. The protective effect of <italic>GSTP1-GG </italic>presence most likely mirrors an increased tolerance to this drug.</p><p>Induction of acute myeloid leukemia is according to Richiardi et al. 38 times more frequent in non-seminoma patients who were treated by etoposide containing chemotherapy compared to the sex-, age-, period, and population-specific incidence rates [<xref ref-type="bibr" rid="B31">31</xref>]. Intriguingly, Allan et al. demonstrated a two-fold prevalence of chemotherapy-induced leukemia among cancer survivors with <italic>GSTP1-GG </italic>compared to those with <italic>GSTP1-AA </italic>or <italic>GSTP1-AG </italic>[<xref ref-type="bibr" rid="B32">32</xref>]. This risk increased to the odds ratio of four in patients who had received known GSTP1 substrates like e.g. cyclofosfamide, etoposide, or adriamycin.</p><p>Induction of leukemia and neurotoxicity by chemotherapy is apparently curbed by strictly opposite GSTP1 polymorphisms. This seemingly contradiction might be due to substrate specificity: Experiments with E.coli cloned with human polymorphic <italic>GSTP1 </italic>indicate that topoisomerase inhibitors are preferentially detoxified by <italic>GSTP1-A </italic>whereas cisplatin is best inactivated by <italic>GSTP1-G </italic>[<xref ref-type="bibr" rid="B33">33</xref>]. The examined SNP A&#x02192;G causes substitution of isoleucine by valine in GSTP1 at codon 105, a residue regulating the affinity and detoxification efficacy for electrophilic substrates [<xref ref-type="bibr" rid="B34">34</xref>]. E.coli with human <italic>GSTP1-G </italic>have a doubled cytoprotection against cisplatin as compared to those with <italic>GSTP1-A</italic>. Recently, <italic>GSTP1-G </italic>was demonstrated to protect patients with gastric cancer against oxaliplatin-induced neuropathy [<xref ref-type="bibr" rid="B35">35</xref>]. Taken together, studies in both bacteriae and cancer patients indicate that <italic>GSTP1-GG </italic>protects its carriers against platinum-induced toxicities.</p><p>The observed beneficial absence of GSTM1 could be explained by a competition on glutathione (GSH) as substrate of both GSTM1 and GSTP1. Both GST-M1 and GST-P1 are co-expressed in the mammalian cochlea and in dorsal root ganglion whose cells are linked to cisplatin-induced paresthesias [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. The latter may detoxify cisplatin more effectively and might unfold more of its protective potential when the competing GSTM1 is not present. Supplementation of GSH demonstrated in a small randomized placebo-controlled study protection against oxaliplatin-induced neurotoxicity [<xref ref-type="bibr" rid="B37">37</xref>].</p><p>Alteration of intracellular apoptosis pathways might represent an alternative or additional explanation to varying detoxification efficacies: GSTP1 monomers bind- and thus inactivate the stress-inducible Jun N-terminal kinase (JNK) [<xref ref-type="bibr" rid="B38">38</xref>]. Oxidative stress releases GSTP1 from JNK, which in turn activates the expression of GSTP1 and other genes involved in apoptosis and cytoprotection [<xref ref-type="bibr" rid="B39">39</xref>]. Inhibition of JNK in cisplatin-treated guinea pigs increased ototoxicity [<xref ref-type="bibr" rid="B40">40</xref>]. Hypothetically, protection against cisplatin-induced toxicities might be due to less effective JNK inactivation by the <italic>GSTP1-G-</italic>derived enzyme GSTP1<sup>105</sup>Val. Intriguingly, GSTM1 was found to be a binding partner of the apoptosis signal-regulating kinase 1 (ASK-1). Binding of ASK-1 by GST-M1 inhibits its function and prevents thereby activation of JNK and p38 pathways [<xref ref-type="bibr" rid="B41">41</xref>]. Deletion of GST-M1, resulting in absence of this functional enzyme might thereby increase the risk of cisplatin-induced apoptosis. We admit that both presented functional explanations of our findings, i.e. interaction with cell signaling factors and competition on glutathione as substrate for both GST-P1 and GST-M1, remain theoretical ones. However, these hypotheses appear readily refuted or supported by cell culture experiments.</p><p>The role of antioxidants for neuro-protection in chemotherapy receiving patients is debated. Pace et al. demonstrated Vitamin E to prevent cisplatin-induced neurotoxicity to some extent,[<xref ref-type="bibr" rid="B42">42</xref>] however, a trial examining calcium- and magnesium salts in oxaliplatin receiving cancer patients had to be stopped due to a lower response rate compared to placebo[<xref ref-type="bibr" rid="B43">43</xref>]. It might be worthwhile to examine neuro-protective effects of antioxidants with respect to potentially important polymorphisms. Glutathione's protective potential might correlate with GST polymorphisms. Hopefully, translation of these findings into clinical practice includes prospective assessment of neuro-protective agents and their modulation by functional polymorphisms.</p><p>Prediction of anticipated toxicities might help patients and oncologists to choose individualized treatment. Therefore, <italic>GST </italic>genotyping might become a helpful tool for avoidance of chemotherapy-induced long-term toxicities. The strongest limitation of our study might represent the reliance on self-reported symptoms only. Objectively measured findings, e.g. nerve conduction velocity and Doppler-flow examination of the digital arteries after cold exposure, would have facilitated the distinction between paresthesias and Raynaud-like phenomena. Furthermore, pre-treatment evaluations are not available, precluding assessment of intra-individual treatment-related changes over time. However, the high compliance-rate of this survey (81%) conducted more than ten years after treatment is considered quite unique and the size and homogeneity of the sample of TCSs might partly compensate for the above mentioned limitations. The observed strong association between SCIN and the cumulative cisplatin-dose permits evaluation of protective genotypes.</p><p>In conclusion, presence of both <italic>GSTP1-G </italic>alleles and/or absence of functional GSTM1 protect its carriers against several chemotherapy-induced long-term toxicities. Before clinical consequences can be discussed, these results should be corroborated in an independent sample of cancer patients. However, the concordance between audiometrically evaluated cisplatin-induced hearing impairment and the observations presented here builds a strong case for the presence of relevant associations between GST polymorphisms and long-term chemotherapy-induced toxicities.</p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Einhorn</surname><given-names>LH</given-names></name></person-group><article-title>Testicular Cancer As A Model for A Curable Neoplasm - the Richard-And-Hinda-Rosenthal-Foundation Award Lecture 1</article-title><source>Cancer Res</source><year>1981</year><volume>41</volume><fpage>3275</fpage><lpage>3280</lpage><pub-id pub-id-type="pmid">6167346</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Einhorn</surname><given-names>LH</given-names></name></person-group><article-title>Curing metastatic testicular cancer</article-title><source>Proc Natl Acad Sci U S A</source><year>2002</year><volume>99</volume><fpage>4592</fpage><lpage>4595</lpage><pub-id pub-id-type="pmid">11904381</pub-id><pub-id pub-id-type="doi">10.1073/pnas.072067999</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fossa</surname><given-names>SD</given-names></name></person-group><article-title>Long-term sequelae after cancer therapy - Survivorship after treatment for testicular cancer</article-title><source>Acta Oncologica</source><year>2004</year><volume>43</volume><fpage>134</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">15163161</pub-id><pub-id pub-id-type="doi">10.1080/02841860310023174</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bokemeyer</surname><given-names>C</given-names></name><name><surname>Berger</surname><given-names>CC</given-names></name><name><surname>Kuczyk</surname><given-names>MA</given-names></name><name><surname>Schmoll</surname><given-names>HJ</given-names></name></person-group><article-title>Evaluation of long-term toxicity after chemotherapy for testicular cancer</article-title><source>J Clin Oncol</source><year>1996</year><volume>14</volume><fpage>2923</fpage><lpage>2932</lpage><pub-id pub-id-type="pmid">8918489</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>SD</given-names></name><name><surname>Birch</surname><given-names>R</given-names></name><name><surname>Einhorn</surname><given-names>LH</given-names></name><name><surname>Irwin</surname><given-names>L</given-names></name><name><surname>Greco</surname><given-names>FA</given-names></name><name><surname>Loehrer</surname><given-names>PJ</given-names></name></person-group><article-title>Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide</article-title><source>The New England Journal Of Medicine</source><year>1987</year><volume>316</volume><fpage>1435</fpage><lpage>1440</lpage><pub-id pub-id-type="pmid">2437455</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Constance</surname><given-names>V</given-names></name></person-group><article-title>Chemotherapy-Induced Peripheral Neuropathy</article-title><source>Cancer Investigation</source><year>2003</year><volume>21</volume><fpage>439</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">12901290</pub-id><pub-id pub-id-type="doi">10.1081/CNV-120018236</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>von Schlippe</surname><given-names>M</given-names></name><name><surname>Fowler</surname><given-names>CJ</given-names></name><name><surname>Harland</surname><given-names>SJ</given-names></name></person-group><article-title>Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis</article-title><source>British Journal of Cancer</source><year>2001</year><volume>85</volume><fpage>823</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">11556831</pub-id><pub-id pub-id-type="doi">10.1054/bjoc.2001.2006</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strumberg</surname><given-names>D</given-names></name><name><surname>Brugge</surname><given-names>S</given-names></name><name><surname>Korn</surname><given-names>MW</given-names></name><name><surname>Koeppen</surname><given-names>S</given-names></name><name><surname>Ranft</surname><given-names>J</given-names></name><name><surname>Scheiber</surname><given-names>G</given-names></name><name><surname>Reiners</surname><given-names>C</given-names></name><name><surname>Mockel</surname><given-names>C</given-names></name><name><surname>Seeber</surname><given-names>S</given-names></name><name><surname>Scheulen</surname><given-names>ME</given-names></name></person-group><article-title>Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer</article-title><source>Ann Oncol</source><year>2002</year><volume>13</volume><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">11885999</pub-id><pub-id pub-id-type="doi">10.1093/annonc/mdf058</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bokemeyer</surname><given-names>C</given-names></name><name><surname>Berger</surname><given-names>CC</given-names></name><name><surname>Hartmann</surname><given-names>JT</given-names></name><name><surname>Kollmannsberger</surname><given-names>C</given-names></name><name><surname>Schmoll</surname><given-names>HJ</given-names></name><name><surname>Kuczyk</surname><given-names>MA</given-names></name><name><surname>Kanz</surname><given-names>L</given-names></name></person-group><article-title>Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer</article-title><source>Br J Cancer</source><year>1998</year><volume>77</volume><fpage>1355</fpage><lpage>1362</lpage><pub-id pub-id-type="pmid">9579846</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stava</surname><given-names>C</given-names></name><name><surname>Beck</surname><given-names>M</given-names></name><name><surname>Schultz</surname><given-names>PN</given-names></name><name><surname>Vassilopoulou-Sellin</surname><given-names>R</given-names></name></person-group><article-title>Hearing loss among cancer survivors 1</article-title><source>Oncology Reports</source><year>2005</year><volume>13</volume><fpage>1193</fpage><lpage>1199</lpage><pub-id pub-id-type="pmid">15870942</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ekborn</surname><given-names>A</given-names></name><name><surname>Laurell</surname><given-names>G</given-names></name><name><surname>Andersson</surname><given-names>A</given-names></name><name><surname>Wallin</surname><given-names>I</given-names></name><name><surname>Eksborg</surname><given-names>S</given-names></name><name><surname>Ehrsson</surname><given-names>H</given-names></name></person-group><article-title>Cisplatin-induced hearing loss: influence of the mode of drug administration in the guinea pig 1</article-title><source>Hearing Research</source><year>2000</year><volume>140</volume><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">10675634</pub-id><pub-id pub-id-type="doi">10.1016/S0378-5955(99)00190-2</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harries</surname><given-names>LW</given-names></name><name><surname>Stubbins</surname><given-names>MJ</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>Howard</surname><given-names>GCW</given-names></name><name><surname>Wolf</surname><given-names>CR</given-names></name></person-group><article-title>Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer</article-title><source>Carcinogenesis</source><year>1997</year><volume>18</volume><fpage>641</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">9111193</pub-id><pub-id pub-id-type="doi">10.1093/carcin/18.4.641</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stoehlmacher</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>DJ</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Groshen</surname><given-names>S</given-names></name><name><surname>Tsao-Wei</surname><given-names>DD</given-names></name><name><surname>Yu</surname><given-names>MC</given-names></name><name><surname>Lenz</surname><given-names>HJ</given-names></name></person-group><article-title>Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer</article-title><source>Journal of the National Cancer Institute</source><year>2002</year><volume>94</volume><fpage>936</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">12072547</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hohaus</surname><given-names>S</given-names></name><name><surname>Di Ruscio</surname><given-names>A</given-names></name><name><surname>Di Febo</surname><given-names>A</given-names></name><name><surname>Massini</surname><given-names>G</given-names></name><name><surname>D'Alo'</surname><given-names>F</given-names></name><name><surname>Guidi</surname><given-names>F</given-names></name><name><surname>Mansueto</surname><given-names>G</given-names></name><name><surname>Voso</surname><given-names>MT</given-names></name><name><surname>Leone</surname><given-names>G</given-names></name></person-group><article-title>Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>2175</fpage><lpage>2179</lpage><pub-id pub-id-type="pmid">15788664</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-1250</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Listowsky</surname><given-names>I</given-names></name><name><surname>Rowe</surname><given-names>JD</given-names></name><name><surname>Patskovsky</surname><given-names>YV</given-names></name><name><surname>Tchaikovskaya</surname><given-names>T</given-names></name><name><surname>Shintani</surname><given-names>N</given-names></name><name><surname>Novikova</surname><given-names>E</given-names></name><name><surname>Nieves</surname><given-names>E</given-names></name></person-group><article-title>Human testicular glutathione S-transferases: insights into tissue-specific expression of the diverse subunit classes</article-title><source>Chem Biol Interact</source><year>1998</year><volume>111-112</volume><fpage>103</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">9679547</pub-id><pub-id pub-id-type="doi">10.1016/S0009-2797(97)00154-3</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Jo</surname><given-names>Y</given-names></name><name><surname>Kinugawa</surname><given-names>K</given-names></name><name><surname>Fujisawa</surname><given-names>M</given-names></name></person-group><article-title>Possible mechanism responsible for the acquisition of resistance to cis-diamminedichloroplatinum (II) by cultured human testicular seminoma cells</article-title><source>Journal of Urology</source><year>2004</year><volume>171</volume><fpage>1929</fpage><lpage>1933</lpage><pub-id pub-id-type="pmid">15076314</pub-id><pub-id pub-id-type="doi">10.1097/01.ju.0000122901.70300.20</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitlon</surname><given-names>DS</given-names></name><name><surname>Wright</surname><given-names>LS</given-names></name><name><surname>Nelson</surname><given-names>SA</given-names></name><name><surname>Szakaly</surname><given-names>R</given-names></name><name><surname>Siegel</surname><given-names>FL</given-names></name></person-group><article-title>Maturation of cochlear glutathione-S-transferases correlates with the end of the sensitive period for ototoxicity 1</article-title><source>Hearing Research</source><year>1999</year><volume>137</volume><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">10545632</pub-id><pub-id pub-id-type="doi">10.1016/S0378-5955(99)00136-7</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Philbert</surname><given-names>MA</given-names></name><name><surname>Beiswanger</surname><given-names>CM</given-names></name><name><surname>Manson</surname><given-names>MM</given-names></name><name><surname>Green</surname><given-names>JA</given-names></name><name><surname>Novak</surname><given-names>RF</given-names></name><name><surname>Primiano</surname><given-names>T</given-names></name><name><surname>Reuhl</surname><given-names>KR</given-names></name><name><surname>Lowndes</surname><given-names>HE</given-names></name></person-group><article-title>Glutathione S-Transferases and Gamma-Glutamyl-Transpeptidase in the Rat Nervous-System - A Basis for Differential Susceptibility to Neurotoxicants</article-title><source>Neurotoxicology</source><year>1995</year><volume>16</volume><fpage>349</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">7566694</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>ES</given-names></name><name><surname>Randon</surname><given-names>KR</given-names></name><name><surname>Knight</surname><given-names>A</given-names></name><name><surname>Windebank</surname><given-names>AJ</given-names></name></person-group><article-title>Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity 195</article-title><source>Neurobiol Dis</source><year>2005</year><volume>18</volume><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">15686959</pub-id><pub-id pub-id-type="doi">10.1016/j.nbd.2004.09.013</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>JD</given-names></name><name><surname>Flanagan</surname><given-names>JU</given-names></name><name><surname>Jowsey</surname><given-names>IR</given-names></name></person-group><article-title>Glutathione transferases 1</article-title><source>Annual Review of Pharmacology and Toxicology</source><year>2005</year><volume>45</volume><fpage>51</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.45.120403.095857</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McIlwain</surname><given-names>CC</given-names></name><name><surname>Townsend</surname><given-names>DM</given-names></name><name><surname>Tew</surname><given-names>KD</given-names></name></person-group><article-title>Glutathione S-transferase polymorphisms: cancer incidence and therapy</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>1639</fpage><lpage>1648</lpage><pub-id pub-id-type="pmid">16550164</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1209373</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oldenburg</surname><given-names>J</given-names></name><name><surname>Kraggerud</surname><given-names>SM</given-names></name><name><surname>Cvancarova</surname><given-names>M</given-names></name><name><surname>Lothe</surname><given-names>RA</given-names></name><name><surname>Fossa</surname><given-names>SD</given-names></name></person-group><article-title>Cisplatin-Induced Long-Term Hearing Impairment Is Associated With Specific Glutathione S-Transferase Genotypes in Testicular Cancer Survivors</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>708</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">17228018</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2006.08.9599</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fossa</surname><given-names>SD</given-names></name><name><surname>Dahl</surname><given-names>AA</given-names></name><name><surname>Loge</surname><given-names>JH</given-names></name></person-group><article-title>Fatigue, anxiety, and depression in long-term survivors of testicular cancer</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>1249</fpage><lpage>1254</lpage><pub-id pub-id-type="pmid">12663711</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2003.08.163</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brydoy</surname><given-names>M</given-names></name><name><surname>Fossa</surname><given-names>SD</given-names></name><name><surname>Klepp</surname><given-names>O</given-names></name><name><surname>Bremnes</surname><given-names>RM</given-names></name><name><surname>Wist</surname><given-names>EA</given-names></name><name><surname>Wentzel-Larsen</surname><given-names>T</given-names></name><name><surname>Dahl</surname><given-names>O</given-names></name></person-group><article-title>Paternity following treatment for testicular cancer</article-title><source>J Natl Cancer Inst</source><year>2005</year><volume>97</volume><fpage>1580</fpage><lpage>1588</lpage><pub-id pub-id-type="pmid">16264178</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kristensen</surname><given-names>T</given-names></name><name><surname>Kristensen</surname><given-names>VN</given-names></name><name><surname>Borresen-Dale</surname><given-names>AL</given-names></name></person-group><article-title>High-throughput screening for known mutations by automated analysis of single sequencing reactions</article-title><source>Biotechniques</source><year>1998</year><volume>24</volume><fpage>832</fpage><lpage>835</lpage><pub-id pub-id-type="pmid">9591134</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fossa</surname><given-names>SD</given-names></name><name><surname>Moynihan</surname><given-names>C</given-names></name><name><surname>Serbouti</surname><given-names>S</given-names></name></person-group><article-title>Patients' and doctors' perception of long-term morbidity in patients with testicular cancer clinical stage I. A descriptive pilot study 7</article-title><source>Support Care Cancer</source><year>1996</year><volume>4</volume><fpage>118</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">8673349</pub-id><pub-id pub-id-type="doi">10.1007/BF01845761</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oldenburg</surname><given-names>J</given-names></name><name><surname>Fossa</surname><given-names>SD</given-names></name><name><surname>Dahl</surname><given-names>AA</given-names></name></person-group><article-title>Scale for chemotherapy-induced long-term neurotoxicity (SCIN): Psychometrics, validation, and findings in a large sample of testicular cancer survivors</article-title><source>Quality of Life Research</source><year>2006</year><volume>15</volume><fpage>791</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">16721639</pub-id><pub-id pub-id-type="doi">10.1007/s11136-005-5370-6</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaltenbach</surname><given-names>JA</given-names></name><name><surname>Rachel</surname><given-names>JD</given-names></name><name><surname>Mathog</surname><given-names>TA</given-names></name><name><surname>Zhang</surname><given-names>JS</given-names></name><name><surname>Falzarano</surname><given-names>PR</given-names></name><name><surname>Lewandowski</surname><given-names>M</given-names></name></person-group><article-title>Cisplatin-induced hyperactivity in the dorsal cochlear nucleus and its relation to outer hair cell loss: Relevance to tinnitus</article-title><source>Journal of Neurophysiology</source><year>2002</year><volume>88</volume><fpage>699</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">12163523</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>N</given-names></name><name><surname>Seidman</surname><given-names>M</given-names></name></person-group><article-title>Tinnitus in the older adult: epidemiology, pathophysiology and treatment options 3</article-title><source>Drugs Aging</source><year>2004</year><volume>21</volume><fpage>297</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">15040757</pub-id><pub-id pub-id-type="doi">10.2165/00002512-200421050-00002</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hausheer</surname><given-names>FH</given-names></name><name><surname>Schilsky</surname><given-names>RL</given-names></name><name><surname>Bain</surname><given-names>S</given-names></name><name><surname>Berghorn</surname><given-names>EJ</given-names></name><name><surname>Lieberman</surname><given-names>F</given-names></name></person-group><article-title>Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy</article-title><source>Seminars in Oncology</source><year>2006</year><volume>33</volume><fpage>15</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">16473643</pub-id><pub-id pub-id-type="doi">10.1053/j.seminoncol.2005.12.010</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richiardi</surname><given-names>L</given-names></name><name><surname>Scelo</surname><given-names>G</given-names></name><name><surname>Boffetta</surname><given-names>P</given-names></name><name><surname>Hemminki</surname><given-names>K</given-names></name><name><surname>Pukkala</surname><given-names>E</given-names></name><name><surname>Olsen</surname><given-names>JH</given-names></name><name><surname>Weiderpass</surname><given-names>E</given-names></name><name><surname>Tracey</surname><given-names>E</given-names></name><name><surname>Brewster</surname><given-names>DH</given-names></name><name><surname>McBride</surname><given-names>ML</given-names></name><name><surname>Kliewer</surname><given-names>EV</given-names></name><name><surname>Tonita</surname><given-names>JM</given-names></name><name><surname>Pompe-Kirn</surname><given-names>V</given-names></name><name><surname>Kee-Seng</surname><given-names>C</given-names></name><name><surname>Jonasson</surname><given-names>JG</given-names></name><name><surname>Martos</surname><given-names>C</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name></person-group><article-title>Second malignancies among survivors of germ-cell testicular cancer: A pooled analysis between 13 cancer registries</article-title><source>International Journal of Cancer</source><year>2007</year><volume>120</volume><fpage>623</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1002/ijc.22345</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allan</surname><given-names>JM</given-names></name><name><surname>Wild</surname><given-names>CP</given-names></name><name><surname>Rollinson</surname><given-names>S</given-names></name><name><surname>Willett</surname><given-names>EV</given-names></name><name><surname>Moorman</surname><given-names>AV</given-names></name><name><surname>Dovey</surname><given-names>GJ</given-names></name><name><surname>Roddam</surname><given-names>PL</given-names></name><name><surname>Roman</surname><given-names>E</given-names></name><name><surname>Cartwright</surname><given-names>RA</given-names></name><name><surname>Morgan</surname><given-names>GJ</given-names></name></person-group><article-title>Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><year>2001</year><volume>98</volume><fpage>11592</fpage><lpage>11597</lpage><pub-id pub-id-type="pmid">11553769</pub-id><pub-id pub-id-type="doi">10.1073/pnas.191211198</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishimoto</surname><given-names>TM</given-names></name><name><surname>Ali-Osman</surname><given-names>F</given-names></name></person-group><article-title>Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli</article-title><source>Pharmacogenetics</source><year>2002</year><volume>12</volume><fpage>543</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">12360105</pub-id><pub-id pub-id-type="doi">10.1097/00008571-200210000-00006</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singhal</surname><given-names>SS</given-names></name><name><surname>Zimniak</surname><given-names>P</given-names></name><name><surname>Awasthi</surname><given-names>S</given-names></name><name><surname>Piper</surname><given-names>JT</given-names></name><name><surname>He</surname><given-names>NG</given-names></name><name><surname>Teng</surname><given-names>JI</given-names></name><name><surname>Petersen</surname><given-names>DR</given-names></name><name><surname>Awasthi</surname><given-names>YC</given-names></name></person-group><article-title>Several closely related glutathione S-transferase isozymes catalyzing conjugation of 4-hydroxynonenal are differentially expressed in human tissues</article-title><source>Arch Biochem Biophys</source><year>1994</year><volume>311</volume><fpage>242</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">8203886</pub-id><pub-id pub-id-type="doi">10.1006/abbi.1994.1233</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lecomte</surname><given-names>T</given-names></name><name><surname>Landi</surname><given-names>B</given-names></name><name><surname>Beaune</surname><given-names>P</given-names></name><name><surname>Laurent-Puig</surname><given-names>P</given-names></name><name><surname>Loriot</surname><given-names>MA</given-names></name></person-group><article-title>Glutathione S-transferase P1 polymorphism (Ile(105)Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>3050</fpage><lpage>3056</lpage><pub-id pub-id-type="pmid">16707601</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-2076</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beiswanger</surname><given-names>CM</given-names></name><name><surname>Diegmann</surname><given-names>MH</given-names></name><name><surname>Novak</surname><given-names>RF</given-names></name><name><surname>Philbert</surname><given-names>MA</given-names></name><name><surname>Graessle</surname><given-names>TL</given-names></name><name><surname>Reuhl</surname><given-names>KR</given-names></name><name><surname>Lowndes</surname><given-names>HE</given-names></name></person-group><article-title>Developmental-Changes in the Cellular-Distribution of Glutathione and Glutathione S-Transferases in the Murine Nervous-System</article-title><source>Neurotoxicology</source><year>1995</year><volume>16</volume><fpage>425</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">8584275</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cascinu</surname><given-names>S</given-names></name><name><surname>Catalano</surname><given-names>V</given-names></name><name><surname>Cordella</surname><given-names>L</given-names></name><name><surname>Labianca</surname><given-names>R</given-names></name><name><surname>Giordani</surname><given-names>P</given-names></name><name><surname>Baldelli</surname><given-names>AM</given-names></name><name><surname>Beretta</surname><given-names>GD</given-names></name><name><surname>Ubiali</surname><given-names>E</given-names></name><name><surname>Catalano</surname><given-names>G</given-names></name></person-group><article-title>Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>3478</fpage><lpage>3483</lpage><pub-id pub-id-type="pmid">12177109</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2002.07.061</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>V</given-names></name><name><surname>Yin</surname><given-names>ZM</given-names></name><name><surname>Fuchs</surname><given-names>SY</given-names></name><name><surname>Benezra</surname><given-names>M</given-names></name><name><surname>Rosario</surname><given-names>L</given-names></name><name><surname>Tew</surname><given-names>KD</given-names></name><name><surname>Pincus</surname><given-names>MR</given-names></name><name><surname>Sardana</surname><given-names>M</given-names></name><name><surname>Henderson</surname><given-names>CJ</given-names></name><name><surname>Wolf</surname><given-names>CR</given-names></name><name><surname>Davis</surname><given-names>RJ</given-names></name><name><surname>Ronai</surname><given-names>Z</given-names></name></person-group><article-title>Regulation of JNK signaling by GSTp</article-title><source>Embo Journal</source><year>1999</year><volume>18</volume><fpage>1321</fpage><lpage>1334</lpage><pub-id pub-id-type="pmid">10064598</pub-id><pub-id pub-id-type="doi">10.1093/emboj/18.5.1321</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>CJ</given-names></name><name><surname>Wolf</surname><given-names>CR</given-names></name></person-group><article-title>Disruption of the glutathione transferase pi class genes</article-title><source>Methods Enzymol</source><year>2005</year><volume>401</volume><fpage>116</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">16399382</pub-id><pub-id pub-id-type="doi">10.1016/S0076-6879(05)01007-4</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ladrech</surname><given-names>S</given-names></name><name><surname>Pujol</surname><given-names>R</given-names></name><name><surname>Brabet</surname><given-names>P</given-names></name><name><surname>Van De Water</surname><given-names>TR</given-names></name><name><surname>Puel</surname><given-names>JL</given-names></name></person-group><article-title>Caspase Inhibitors, but not c-Jun NH2-Terminal Kinase Inhibitor Treatment, Prevent Cisplatin-Induced Hearing Loss</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>9217</fpage><lpage>9224</lpage><pub-id pub-id-type="pmid">15604295</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1581</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>SG</given-names></name><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Park</surname><given-names>HS</given-names></name><name><surname>Ryoo</surname><given-names>K</given-names></name><name><surname>Kang</surname><given-names>KW</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Eom</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Chang</surname><given-names>TS</given-names></name><name><surname>Choi</surname><given-names>SY</given-names></name><name><surname>Shim</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>SG</given-names></name><name><surname>Ichijo</surname><given-names>H</given-names></name><name><surname>Choi</surname><given-names>EJ</given-names></name></person-group><article-title>Glutathione S-transferase Mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1</article-title><source>Journal of Biological Chemistry</source><year>2001</year><volume>276</volume><fpage>12749</fpage><lpage>12755</lpage><pub-id pub-id-type="pmid">11278289</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M005561200</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pace</surname><given-names>A</given-names></name><name><surname>Savarese</surname><given-names>A</given-names></name><name><surname>Picardo</surname><given-names>M</given-names></name><name><surname>Maresca</surname><given-names>V</given-names></name><name><surname>Pacetti</surname><given-names>U</given-names></name><name><surname>Del Monte</surname><given-names>G</given-names></name><name><surname>Biroccio</surname><given-names>A</given-names></name><name><surname>Leonetti</surname><given-names>C</given-names></name><name><surname>Jandolo</surname><given-names>B</given-names></name><name><surname>Cognetti</surname><given-names>F</given-names></name><name><surname>Bove</surname><given-names>L</given-names></name></person-group><article-title>Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>927</fpage><lpage>931</lpage><pub-id pub-id-type="pmid">12610195</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2003.05.139</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochster</surname><given-names>HS</given-names></name><name><surname>Grothey</surname><given-names>A</given-names></name><name><surname>Childs</surname><given-names>BH</given-names></name></person-group><article-title>Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>4028</fpage><lpage>4029</lpage><pub-id pub-id-type="pmid">17664456</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2007.13.5251</pub-id></citation></ref></ref-list></back></article> 